Patients treated with radical prostatectomy with positive digital rectal examination findings in the intermediate-risk group are prone to PSA recurrence

The present study aimed to evaluate the possibility of performing radical prostatectomy (RP) alone to achieve a radical cure for prostate cancer in the intermediate-risk group. Samples were collected from 638 Japanese patients who underwent antegrade RP between August 1998 and May 2013; subsequently, 157 patients were excluded. According to the D'Amico criteria, the low-, intermediate- and high-risk groups comprised 107, 222 and 152 patients, respectively. The 5-year prostate-specific antigen (PSA) failure-free survival rates in the low-, intermediate-, and high-risk groups were 96.5, 88.9 and 72.6%, respectively (P<0.001; degrees of freedom=2). In the intermediate-risk group, the difference in PSA failure-free survival between the 0<PSA≤10 and 10<PSA≤20 ng/ml, and the biopsy Gleason score 6 and 7 groups were not statistically significant, according to the log-rank test (P=0.2266 and P=0.1329, respectively). However, the difference in PSA failure-free survival between the clinical tumor stage (cT)1c and cT2a/b groups was statistically significant based on the log-rank test (P<0.0001). The results of the multivariate analysis revealed that, of the preoperative characteristics, only the cT was a significant predictor in patients with and without PSA failure (P<0.001). Therefore, patients classified into the intermediate-risk group with cT2a/b stage, according to positive digital rectal examination findings, and are not considered to be likely to achieve a complete cure with RP surgery alone. In summary, for patients meeting these criteria in the intermediate-risk group, RP surgery alone is likely to be insufficient, and other additional treatments may be considered subsequent to RP.

Oncology letters. 2016 Apr 20 [Epub]

Nobuki Furubayashi, Takahito Negishi, Shintaro Ura, Jun Mutaguchi, Kenichi Taguchi, Mototsugu Shimokawa, Motonobu Nakamura

Department of Urology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan., Department of Urology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan., Department of Urology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan., Department of Urology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan., Department of Pathology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan., Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan., Department of Urology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe